186 related articles for article (PubMed ID: 18239941)
1. Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma.
Pye A; Campbell S; Curnow A
J Cancer Res Clin Oncol; 2008 Aug; 134(8):841-9. PubMed ID: 18239941
[TBL] [Abstract][Full Text] [Related]
2. Direct comparison of delta-aminolevulinic acid and methyl-aminolevulinate-derived protoporphyrin IX accumulations potentiated by desferrioxamine or the novel hydroxypyridinone iron chelator CP94 in cultured human cells.
Pye A; Curnow A
Photochem Photobiol; 2007; 83(3):766-73. PubMed ID: 17576385
[TBL] [Abstract][Full Text] [Related]
3. The effects of protoporphyrin IX-induced photodynamic therapy with and without iron chelation on human squamous carcinoma cells cultured under normoxic, hypoxic and hyperoxic conditions.
Blake E; Allen J; Curnow A
Photodiagnosis Photodyn Ther; 2013 Dec; 10(4):575-82. PubMed ID: 24284114
[TBL] [Abstract][Full Text] [Related]
4. An experimental investigation of a novel iron chelating protoporphyrin IX prodrug for the enhancement of photodynamic therapy.
Anayo L; Magnussen A; Perry A; Wood M; Curnow A
Lasers Surg Med; 2018 Jul; 50(5):552-565. PubMed ID: 29603761
[TBL] [Abstract][Full Text] [Related]
5. Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma.
Campbell SM; Morton CA; Alyahya R; Horton S; Pye A; Curnow A
Br J Dermatol; 2008 Aug; 159(2):387-93. PubMed ID: 18544077
[TBL] [Abstract][Full Text] [Related]
6. Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma: further explanation of a dose-escalating pilot study conducted primarily to consider the safety of this pharmacological modification.
Curnow A; Campbell SM
Br J Dermatol; 2010 Jan; 162(1):224-5. PubMed ID: 19903172
[No Abstract] [Full Text] [Related]
7. The hydroxypyridinone iron chelator CP94 increases methyl-aminolevulinate-based photodynamic cell killing by increasing the generation of reactive oxygen species.
Dogra Y; Ferguson DCJ; Dodd NJF; Smerdon GR; Curnow A; Winyard PG
Redox Biol; 2016 Oct; 9():90-99. PubMed ID: 27454766
[TBL] [Abstract][Full Text] [Related]
8. An in vitro comparison of the effects of the iron-chelating agents, CP94 and dexrazoxane, on protoporphyrin IX accumulation for photodynamic therapy and/or fluorescence guided resection.
Blake E; Allen J; Curnow A
Photochem Photobiol; 2011; 87(6):1419-26. PubMed ID: 21834866
[TBL] [Abstract][Full Text] [Related]
9. Biochemical manipulation via iron chelation to enhance porphyrin production from porphyrin precursors.
Curnow A; Pye A
J Environ Pathol Toxicol Oncol; 2007; 26(2):89-103. PubMed ID: 17725535
[TBL] [Abstract][Full Text] [Related]
10. The hydroxypyridinone iron chelator CP94 can enhance PpIX-induced PDT of cultured human glioma cells.
Blake E; Curnow A
Photochem Photobiol; 2010; 86(5):1154-60. PubMed ID: 20573043
[TBL] [Abstract][Full Text] [Related]
11. Improving in vitro photodynamic therapy through the development of a novel iron chelating aminolaevulinic acid prodrug.
Curnow A; Perry A; Wood M
Photodiagnosis Photodyn Ther; 2019 Mar; 25():157-165. PubMed ID: 30553949
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of an iron chelator (CP94) in increasing cellular protoporphyrin IX following intravesical 5-aminolaevulinic acid administration: an in vivo study.
Chang SC; MacRobert AJ; Porter JB; Bown SG
J Photochem Photobiol B; 1997 Apr; 38(2-3):114-22. PubMed ID: 9203372
[TBL] [Abstract][Full Text] [Related]
13. Experimental investigation of a combinational iron chelating protoporphyrin IX prodrug for fluorescence detection and photodynamic therapy.
Magnussen A; Reburn C; Perry A; Wood M; Curnow A
Lasers Med Sci; 2022 Mar; 37(2):1155-1166. PubMed ID: 34218351
[TBL] [Abstract][Full Text] [Related]
14. Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma: when statistics make a difference.
Mangano A; Albertin A; La Colla L
Br J Dermatol; 2009 Jul; 161(1):215-6. PubMed ID: 19438852
[No Abstract] [Full Text] [Related]
15. The relationship between protoporphyrin IX photobleaching during real-time dermatological methyl-aminolevulinate photodynamic therapy (MAL-PDT) and subsequent clinical outcome.
Tyrrell JS; Campbell SM; Curnow A
Lasers Surg Med; 2010 Sep; 42(7):613-9. PubMed ID: 20806386
[TBL] [Abstract][Full Text] [Related]
16. The time-dependent accumulation of protoporphyrin IX fluorescence in nodular basal cell carcinoma following application of methyl aminolevulinate with an oxygen pressure injection device.
Blake E; Campbell S; Allen J; Mathew J; Helliwell P; Curnow A
J Photochem Photobiol B; 2012 Dec; 117():97-103. PubMed ID: 23092624
[TBL] [Abstract][Full Text] [Related]
17. Effect of an oxygen pressure injection (OPI) device on the oxygen saturation of patients during dermatological methyl aminolevulinate photodynamic therapy.
Blake E; Allen J; Thorn C; Shore A; Curnow A
Lasers Med Sci; 2013 May; 28(3):997-1005. PubMed ID: 22926533
[TBL] [Abstract][Full Text] [Related]
18. Monitoring the accumulation and dissipation of the photosensitizer protoporphyrin IX during standard dermatological methyl-aminolevulinate photodynamic therapy utilizing non-invasive fluorescence imaging and quantification.
Tyrrell J; Campbell SM; Curnow A
Photodiagnosis Photodyn Ther; 2011 Mar; 8(1):30-8. PubMed ID: 21333932
[TBL] [Abstract][Full Text] [Related]
19. Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma.
Kuijpers DI; Thissen MR; Thissen CA; Neumann MH
J Drugs Dermatol; 2006; 5(7):642-5. PubMed ID: 16865869
[TBL] [Abstract][Full Text] [Related]
20. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial.
Rhodes LE; de Rie M; Enström Y; Groves R; Morken T; Goulden V; Wong GA; Grob JJ; Varma S; Wolf P
Arch Dermatol; 2004 Jan; 140(1):17-23. PubMed ID: 14732655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
